HSAC2 gets redemption requests for 9.2M shares; RTW Funds buys 1M shares at $10.01 to back Orchestra BioMed deal

Orchestra BioMed Holdings, Inc.

As of July 22, 2022, shareholders requested redemption of 9,237,883 HSAC2 ordinary shares ahead of July 26 vote on extension to Nov 6, 2022.
RTW Funds (manager affiliate) purchased 1,000,000 HSAC2 shares at $10.01/share from an accredited investor in a private transaction.
Purchase fulfills RTW's obligations under Forward Purchase Agreement with HSAC2 and Orchestra BioMed, and prevents redemption of those shares to retain trust funds.
The action increases likelihood that the proposed business combination with Orchestra BioMed ultimately closes.
The extension proposal would allow additional monthly extensions up to February 6, 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.